The effectiveness of Rivastigmine on treatment of Tardive dyskinesia
Phase 2
- Conditions
- Tardive dyskinesia.Drug-induced dystonia
- Registration Number
- IRCT2012092910964N1
- Lead Sponsor
- niversity of Social Welfare and Rehabilitation Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Male
- Target Recruitment
- 40
Inclusion Criteria
Age range between 18 to 65 years, Spent at least one year of treatment with antipsychotics, to have a stable condition of the patient for at least one month prior to study entry.
Exclusion criteria: Organic brain disease, Any neurological disorders, Having a chronic health problem, Change in the amount or type of antipsychotic medication or tranquilizers were used during the last 6 months so that might affect the patient's motor symptoms, Patients with mental retardation, Patients with thyroid disorders, Diabetes, and Substance Abusers.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Tardive dyskinesia symptoms. Timepoint: At baseline and after eight weeks follow-up. Method of measurement: Abnormal Involuntary Movement Scale (AIMS).
- Secondary Outcome Measures
Name Time Method